Immatics Price to Sales Trend from 2010 to 2022

IMTX -  USA Stock  

USD 10.32  0.35  3.51%

Immatics Interest Expense is fairly stable at the moment as compared to the past year. Immatics reported Interest Expense of 11.57 Million in 2021. Net Income to Non Controlling Interests is likely to rise to about 598.4 K in 2022, whereas Consolidated Income is likely to drop (195.7 M) in 2022.

Immatics Historical Trends 

 
Refresh
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Gross Profit of 29.2 M, Interest Expense of 12.5 M or Net Income to Non Controlling Interests of 598.4 K, as well as many exotic indicators such as Asset Turnover of 0.18, Book Value per Share of 2.26 or Current Ratio of 3.21. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules. It can also supplement various Immatics Technical models. Please see the analysis of Immatics Correlation against competitors.

Immatics Price to Sales Breakdown

Showing smoothed Price to Sales Ratio of Immatics NV with missing and latest data points interpolated. Price to Sales Ratio is figured by comparing Immatics NV stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immatics sales, a figure that is much harder to manipulate than other Immatics NV multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. An alternative calculation method to [PS]; that measures the ratio between a company's [Price] and it's [SPS].Immatics' Price to Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 23.28 X10 Years Trend
 Price to Sales Ratio 
Share
      Timeline 

Immatics Price to Sales Regression Statistics

Arithmetic Mean 56.04
Geometric Mean 44.33
Coefficient Of Variation 52.40
Mean Deviation 26.03
Median 74.84
Standard Deviation 29.37
Sample Variance 862.48
Range 62.61
R-Value(0.81)
Mean Square Error 329.28
R-Squared 0.65
Significance 0.00087191
Slope(6.08)
Total Sum of Squares 10,350

Immatics Price to Sales History

2019  16.60 
2020  13.59 
2021  12.23 
2022  12.55 

About Immatics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's Price to Sales, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Price to Sales Ratio 12.23  12.55 
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications Amgen Inc. and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 331 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immatics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immatics Correlation against competitors. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.